Anti-inflammatory agents and monoHER protect against DOX-induced cardiotoxicity and accumulation of CML in mice
- PMID: 17325706
- PMCID: PMC2360105
- DOI: 10.1038/sj.bjc.6603640
Anti-inflammatory agents and monoHER protect against DOX-induced cardiotoxicity and accumulation of CML in mice
Abstract
Cardiac damage is the major limiting factor for the clinical use of doxorubicin (DOX). Preclinical studies indicate that inflammatory effects may be involved in DOX-induced cardiotoxicity. Nepsilon-(carboxymethyl) lysine (CML) is suggested to be generated subsequent to oxidative stress, including inflammation. Therefore, the aim of this study was to investigate whether CML increased in the heart after DOX and whether anti-inflammatory agents reduced this effect in addition to their possible protection on DOX-induced cardiotoxicity. These effects were compared with those of the potential cardioprotector 7-monohydroxyethylrutoside (monoHER).BALB/c mice were treated with saline, DOX alone or DOX preceded by ketoprofen (KP), dexamethasone (DEX) or monoHER. Cardiac damage was evaluated according to Billingham. Nepsilon-(carboxymethyl) lysine was quantified immunohistochemically. Compared to saline, a 21.6-fold increase of damaged cardiomyocytes was observed in mice treated with DOX (P<0.001). Addition of KP, DEX or monoHER before DOX significantly reduced the mean ratio of abnormal cardiomyocytes in comparison to mice treated with DOX alone (P<or=0.02). In addition, DOX induced a significant increase in the number of CML-stained intramyocardial vessels per mm2 (P=0.001) and also in the intensity of CML staining (P=0.001) compared with the saline-treated group. Nepsilon-(carboxymethyl) lysine positivity was significantly reduced (P<or=0.01) by DOX-DEX, DOX-KP and DOX-monoHER. These results confirm that inflammation plays a role in DOX-induced cardiotoxicity, which is strengthened by the observed DOX-induced accumulation of CML, which can be reduced by anti-inflammatory agents and monoHER.
Figures


Similar articles
-
The influence of the time interval between monoHER and doxorubicin administration on the protection against doxorubicin-induced cardiotoxicity in mice.Cancer Chemother Pharmacol. 2006 Nov;58(5):699-702. doi: 10.1007/s00280-006-0206-9. Epub 2006 Mar 25. Cancer Chemother Pharmacol. 2006. PMID: 16565833
-
Long-term effects of 7-monohydroxyethylrutoside (monoHER) on DOX-induced cardiotoxicity in mice.Cancer Chemother Pharmacol. 2007 Sep;60(4):509-14. doi: 10.1007/s00280-006-0395-2. Epub 2006 Dec 20. Cancer Chemother Pharmacol. 2007. PMID: 17177067
-
A comparative study between catalase gene therapy and the cardioprotector monohydroxyethylrutoside (MonoHER) in protecting against doxorubicin-induced cardiotoxicity in vitro.Br J Cancer. 2003 Dec 1;89(11):2140-6. doi: 10.1038/sj.bjc.6601430. Br J Cancer. 2003. PMID: 14647150 Free PMC article.
-
Monohydroxyethylrutoside, a dose-dependent cardioprotective agent, does not affect the antitumor activity of doxorubicin.Clin Cancer Res. 1997 Oct;3(10):1747-54. Clin Cancer Res. 1997. PMID: 9815559
-
The protective effect of cardiac gene transfer of CuZn-sod in comparison with the cardioprotector monohydroxyethylrutoside against doxorubicin-induced cardiotoxicity in cultured cells.Cancer Gene Ther. 2003 Apr;10(4):270-7. doi: 10.1038/sj.cgt.7700564. Cancer Gene Ther. 2003. PMID: 12679799
Cited by
-
Small molecule kinase inhibitors block the ZAK-dependent inflammatory effects of doxorubicin.Cancer Biol Ther. 2013 Jan;14(1):56-63. doi: 10.4161/cbt.22628. Epub 2012 Oct 31. Cancer Biol Ther. 2013. PMID: 23114643 Free PMC article.
-
Advantages of prophylactic versus conventionally scheduled heart failure therapy in an experimental model of doxorubicin-induced cardiomyopathy.J Transl Med. 2019 Jul 19;17(1):229. doi: 10.1186/s12967-019-1978-0. J Transl Med. 2019. PMID: 31324258 Free PMC article.
-
Inflammation in Chemotherapy-Induced Cardiotoxicity.Curr Cardiol Rep. 2024 Dec;26(12):1329-1340. doi: 10.1007/s11886-024-02131-5. Epub 2024 Oct 8. Curr Cardiol Rep. 2024. PMID: 39377963 Free PMC article. Review.
-
Cardiac inflammation and microvascular procoagulant changes are decreased in second wave compared to first wave deceased COVID-19 patients.Int J Cardiol. 2022 Feb 15;349:157-165. doi: 10.1016/j.ijcard.2021.11.079. Epub 2021 Dec 3. Int J Cardiol. 2022. PMID: 34871622 Free PMC article.
-
Toll-like receptor (TLR) 2 and TLR4 differentially regulate doxorubicin induced cardiomyopathy in mice.PLoS One. 2012;7(7):e40763. doi: 10.1371/journal.pone.0040763. Epub 2012 Jul 13. PLoS One. 2012. PMID: 22808256 Free PMC article.
References
-
- Anderson MM, Heinecke JW (2003) Production of N (epsilon)-(carboxymethyl)lysine is impaired in mice deficient in NADPH oxidase: a role for phagocyte-derived oxidants in the formation of advanced glycation end products during inflammation. Diabetes 52: 2137–2143 - PubMed
-
- Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M (1995) Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 270: 286–290 - PubMed
-
- Baeuerle PA (1991) The inducible transcription activator NF-κB: regulation by distinct protein subunits. Biochim Biophys Acta 1072: 63–80 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical